Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Compugen Announces Collaboration and License Agreement with Bayer

Published: Tuesday, August 06, 2013
Last Updated: Tuesday, August 06, 2013
Bookmark and Share
Compugen to hold 2nd Quarter Conference Call August 7, 2013.

Compugen Ltd. has announced the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators.

Under the terms of the agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a preclinical research program.

Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics.

Under the agreement Compugen will receive an upfront payment of USD 10 million, and is eligible to receive over USD 500 million in potential milestone payments for both programs, not including milestone payments of up to USD 30 million associated with preclinical activities.

Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.

“Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer live longer and improve their quality of life,” said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery.

Prof. Busch continued, “Antibody-based immunotherapies are promising approaches in oncology which can stimulate the body’s own immune cells to fight cancer cells. Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen.”

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, “We are very excited to initiate this collaboration with Bayer, a leading global life science company with a broadening oncology franchise, for the development of antibody-based cancer immunotherapies against these two promising novel immune checkpoint targets. In addition, we believe that the prediction and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability".

The immunotherapy approach aims at combatting cancer by stimulating the body's own immune cells. The tumor and its environment suppress the ability of cancer patients to develop an effective anti-tumor immune response and in this way protect both tumor growth and survival.

Compugen has discovered two novel immune checkpoint regulators that potentially play a key role in immunosuppression.

Researchers at Compugen are developing specific therapeutic antibodies that are geared to block the immunosuppressive function of these targets and to reactivate the patient's anti-tumor immune response in order to fight cancer.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Discloses New Results Supporting CGEN-15052
Data presented at the Inaugural International Cancer Immunotherapy Conference in New York City.
Thursday, September 17, 2015
Compugen Discloses Initial Experimental Results for Predicted ADC Targets
Pipeline program for oncology to be further expanded and diversified with addition of ADC therapeutic programs to ongoing immuno-oncology programs.
Tuesday, January 06, 2015
Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins
Incorporation of algorithms modeling additional biological phenomena leads to predictive discovery of four potential immunomodulatory targets.
Tuesday, July 15, 2014
Compugen Reports Fourth Quarter and Calendar 2013 Results
Company discloses key 2014 corporate objectives.
Wednesday, February 12, 2014
Compugen Announces Addition of Prof. Drew Pardoll to its SAB
Prof. Pardoll is a world leader in immuno-oncology research and in the development of novel cancer therapeutics.
Wednesday, January 22, 2014
Compugen Discloses Discovery of Five Potential Cancer Targets for ADC Therapy
ADC target discovery is company’s second focused discovery program utilizing its in silico predictive discovery infrastructure.
Thursday, December 12, 2013
Compugen Target for Cancer Immunotherapy Shown to Affect Multiple Immune Cell Types
CGEN-15049 immune checkpoint protein expressed on wide variety of cancers.
Thursday, September 26, 2013
Compugen Establishes SAB to Guide Pipeline Program Development
Key opinion leaders to advise Company on research and development involving therapeutic product candidates in the fields of immunology and oncology.
Tuesday, August 27, 2013
Compugen Discloses Focused Target Discovery Program for ADC Cancer Therapy
Initial discoveries from new program anticipated before year-end.
Tuesday, April 09, 2013
Compugen Announces Discovery of Two Drug Target Candidates for mAb Cancer Therapy
Targets are expressed in multiple cancers and have a distinct mode of action inhibiting two key immune cell subsets.
Tuesday, March 05, 2013
Compugen Announces Validation Results for a Second Potential Immune Checkpoint Target for Cancer Immunotherapy
Expression levels of CGEN-15022 demonstrated in various types of epithelial cancers with significant unmet clinical needs, including liver, colorectal, lung and ovarian cancer.
Friday, June 29, 2012
Compugen Presents Prediction Based Discovery Strategy at “Targets and Strategies for Drug Discovery” Conference
Presentation includes disclosure of CGEN-15022 and CGEN-15092 as target candidates for antibody based cancer immunotherapy.
Tuesday, February 28, 2012
Compugen Reports Fourth Quarter and Calendar 2011 Financial Results Feb 07, 2012
Immunomodulatory therapeutics program being extended beyond B7/CD28 family.
Thursday, February 09, 2012
Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Findings support CGEN-15001T's potential as a powerful drug target for cancer immunotherapy.
Monday, February 06, 2012
Compugen Discovers Drug Target for Treatment of Epithelial Tumors
Existence and utility of CGEN-671 predicted in silico through use of Compugen’s monoclonal antibody targets discovery platform.
Tuesday, December 29, 2009
Scientific News
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Gene-Edited Immune Cells Treat ‘Incurable’ Leukaemia
A new treatment that uses ‘molecular scissors’ to edit genes and create designer immune cells programmed to hunt out and kill drug resistant leukaemia has been used at Great Ormond Street Hospital (GOSH).

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos